(Press-News.org) Barcelona, 17 October 2013. A multicentre phase III study, with centers participating from 11 countries in North America, Europe and Australia, shows that the drug combination nab-paclitaxel and gemcitabine is more effective in the treatment of patients with advanced pancreatic cancer than gemcitabine alone, which has been the standard treatment for these patients up until now.
The clinical trial, sponsored by Celgene Corporation, involved 861 patients, half of whom were administered the nab-paclitaxel/gemcitabine combination, while the other half received gemcitabine alone. Median overall survival was 8.5 months for nab-paclitaxel/gemcitabine versus 6.7 months for gemcitabine alone. One-year survival rates were 35% and 22%, respectively, and two-year survival rates were 9% and 4%, respectively. Similar side effects were found in the new drug and gemcitabine alike. The trial report therefore concluded that the nab-paclitaxel/gemcitabine combination significantly improves overall survival and response rate in patients with advanced pancreatic cancer.
Dr Josep Tabernero, Head of the Medical Oncology Department at the Vall d´Hebron University Hospital, Director of the Vall d´Hebron Institute of Oncology (VHIO), and one of the co-authors of the study, confirmed that "the results of this study take a step in the right direction towards controlling advanced pancreatic cancer, a disease with a very poor prognosis. We are confident that the gemcitabine/nab-paclitaxel combination will become one of the reference treatments for this disease. New drugs in the pipeline in this field are already being gauged against this combination as the benchmark to beat. Along these lines, investigators at VHIO are developing promising laboratory model combinations for pancreatic cancer treatment."
New first-line treatment for pancreatic cancer
Pancreatic cancer is the fourth leading cause of cancer-related death in Europe and the United States. Gemcitabine therapy has been the standard first-line treatment in patients with unresectable, locally advanced or metastatic pancreatic cancer since 1997. In metastatic disease, one-year survival ranges from about 17 to 23%, while five-year survival is only 2%.
Although numerous phase II and III studies have been conducted on new drugs combined with gemcitabine, most have not shown significant improvement in survival among these patients. The nab-paclitaxel/gemcitabine combination opens a new treatment avenue in this patient population.
###
For more information contact:
Amanda Wren
Communication Manager
Vall d´Hebron Institute of Oncology (VHIO)
Tel. +34 695207886
Email: awren@vhio.net
Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO), have participated in an international phase III study, published in The New England Journal of Medicine. Results show that administering these two drugs in combination significantly improves one- and two-year survival in patients with advanced pancreatic cancer versus gemcitabine alone, the first-line treatment or most standard approach for this type of cancer to date.
The new drug is set to become a reference in advanced pancreatic cancer treatment.
2-drug combination, nab-paclitaxel and gemcitabine, improves survival in pancreatic cancer
2013-10-17
ELSE PRESS RELEASES FROM THIS DATE:
Scientists prove Heisenberg's intuition correct
2013-10-17
An international team of scientists has provided proof of a key feature of quantum physics – Heisenberg's error-disturbance relation - more than 80 years after it was first suggested.
One of the basic concepts in the world of quantum mechanics is that it is impossible to observe physical objects without affecting them in a significant way; there can be no measurement without disturbance.
In a paper in 1927, Werner Heisenberg, one of the architects of the fundamental theories of modern physics, claimed that this fact could be expressed as an uncertainty relation, describing ...
Does genetic variability affect long-term response to traumatic brain injury?
2013-10-17
New Rochelle, NY, October 17, 2013 -- An individual's recovery months after a traumatic brain injury (TBI) is difficult to predict, and some of the variability in outcomes may be due to genetic differences. Subtle variations in genes that regulate a person's inflammatory response to injury can impact clinical outcomes in TBI, according to a new study published in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Neurotrauma website at http://www.liebertpub.com/neu.
In the article "Cytokine ...
The complicated birth of a volcano
2013-10-17
Snow storms, ice and glaciers - these are the usual images we associate with the Antarctic. But at the same time it is also a region of fire: the Antarctic continent and surrounding waters are dotted with volcanoes - some of them still active and others extinct for quite some time. The Marie Byrd Seamounts in the Amundsen Sea are in the latter group. Their summit plateaus are today at depths of 2400-1600 meters. Because they are very difficult to reach with conventional research vessels, they have hardly been explored, even though the Marie Byrd Seamounts are fascinating ...
Archaeologists rediscover the lost home of the last Neanderthals
2013-10-17
A record of Neanderthal archaeology, thought to be long lost, has been re-discovered by NERC-funded scientists working in the Channel island of Jersey.
The study, published yesterday in the Journal of Quaternary Science, reveals that a key archaeological site has preserved geological deposits which were thought to have been lost through excavation 100 years ago.
The discovery was made when the team undertook fieldwork to stabilise and investigate a portion of the La Cotte de St Brelade cave, on Jersey's south eastern coastline.
A large portion of the site contains ...
Neanderthals used toothpicks to alleviate the pain of diseases such as inflammation of the gums
2013-10-17
Removing food scraps trapped between the teeth one of the most common functions of using toothpicks, thus contributing to our oral hygiene. This habit is documented in the genus Homo, as early as Homo habilis, a species that lived between 1.9 and 1.6 million years ago. A new research based on the Cova Foradà Neanderthal fossil shows that this hominid also used toothpicks to mitigate pain caused by oral diseases such as inflammation of the gums (periodontal disease). It is the oldest documented case of palliative treatment of dental disease done with this tool.
It is stated ...
Uncovering liquid foam's bubbly acoustics
2013-10-17
Liquid foams fascinate toddlers singing in a bubble bath. Physicists, too, have an interest in their acoustical properties. Borrowing from both porous material and foam science, Juliette Pierre from the Paris Diderot University, Paris, France and her colleagues studied liquid foams. They used an impedance tube to measure the velocity and attenuation of acoustic waves in liquid foams in a broad frequency range. The study published in EPJ E is a first in the literature. It could help in assessing any liquid foam's bubble size or in designing the optimal foam structure for ...
Is a constructive conservation the last chance for biodiversity?
2013-10-17
In a human-dominated world that contains only little "historical" nature, the term ecosystem can no longer be a synonym for unspoilt nature. The term "novel ecosystems" was coined a few years ago to describe disturbed ecosystems, in which biodiversity has been significantly altered as the result of human intervention. "In our new conservation framework we argue that this strict distinction between historic and novel ecosystems should be reconsidered to aid conservation", pollination biologist Dr. Christopher Kaiser-Bunbury describes the approach, which is not without controversy.
On ...
Transcription factors: Function follows form
2013-10-17
This news release is available in German. Clay can be used in various forms for a range of objects such as cups, plates or bricks. Similarly, proteins can transform their structure and thus adapt their function and activity. Researchers at the Max Planck Institute for Molecular Genetics in Berlin have analysed proteins for such modifications that control gene activity, so-called transcription factors. The researchers thereby discovered that DNA changes the form and the activity of the glucocorticoid receptor, and also ascertained how various domains in the molecule ...
World's first mapping of America's rare plants
2013-10-17
In collaboration with international colleagues, a research group at Aarhus University, Denmark, has contributed to the compilation of the most comprehensive botanical data set to date. PhD student Naia Morueta-Holme and her supervisor, Professor Jens-Christian Svenning, Department of Bioscience, spearheaded the analysis that reveals where rare species are found in the New World (North and South America) and the factors that determine whether a region is dominated by widespread or rare species.
"The study shows that especially California, Mexico, the Caribbean islands, ...
CHOP's Harvest toolkit offers innovative data discovery resource for biomedical researchers
2013-10-17
Biomedical researchers often confront large quantities of information that may be amassed in many forms: vital signs, blood cell counts, lengthy DNA sequences, bar graphs, MRIs, patient demographics, and so much more. How do researchers assemble, access and analyze all that data without having to become specialized database technicians themselves?
A team of informatics experts and biomedical researchers at The Children's Hospital of Philadelphia (CHOP) offers a new software toolkit to help researchers wrangle data. Their open-source, highly interactive framework called ...